Catalog No.
Product Name
Application
Product Information
Citations
-
Somatostatin Receptor Antagonist
SRA880 is a selective antagonist of the somatostatin receptor subtype sst(1). This non-peptide compound has demonstrated antidepressant-like effects, particularly in conjunction with Imipramine. SRA880 can be utilized in research applications focused on mood disorders and somatostatin signaling pathways, contributing valuable insights into potential therapeutic mechanisms. -
SSTR Agonist
Veldoreotide TFA is a somatostatin analogue that acts as an agonist for somatostatin receptors (SSTR) 2, 4, and 5. This compound effectively inhibits growth hormone (GH) secretion in adenomas, demonstrating enhanced efficacy compared to other somatostatin analogues. Additionally, Veldoreotide TFA shows promise as a pain-modulating agent, making it valuable in research applications related to endocrine and pain pathways. -
Somatostatin Receptor Agonist
Somatostatin-28 (1-14) serves as an agonist of somatostatin receptors. This N-terminal fragment of the neuropeptide somatostatin-28 plays a critical role in regulating various physiological processes, including hormone secretion and neurotransmission. It is widely used in research applications investigating metabolic regulation, neurobiology, and potential therapeutic strategies for neuroendocrine disorders. -
Antineoplastic Agent
Lanreotide is a somatostatin analogue that exhibits antineoplastic properties by inhibiting growth hormone and other peptide hormone secretions. It is primarily utilized in the study of carcinoid syndrome and other neuroendocrine tumors due to its ability to suppress tumor growth and hormonal activity. This compound provides a valuable tool for researchers investigating hormone-related cancers and their management. -
SSTR5 Antagonist
SSTR5 antagonist 2 hydrochloride is a potent and selective antagonist of the somatostatin receptor subtype 5 (SSTR5). This compound demonstrates significant biological activity in modulating SSTR5 signaling pathways, making it a valuable tool for investigating the role of somatostatin in various physiological and pathological processes. It is particularly relevant for research applications related to type 2 diabetes mellitus (T2DM) and other metabolic disorders. -
Somatostatin Receptor Agonist
L-817818 is a potent and subtype-selective agonist of the somatostatin receptor. This compound facilitates the exploration of somatostatin receptor physiological functions, contributing to a better understanding of its role in various biological processes. It is useful for research applications aimed at studying neuroendocrine regulation and potential therapeutic targets related to somatostatin signaling. -
SSTR2 Agonist
Seglitide acetate is a potent agonist of the somatostatin receptor 2 (SSTR2) and serves as a competitive antagonist of SSTR14, SSTR25, and SSTR28. It exhibits significant antihypertensive properties and has the capability to inhibit plasma glucagon and growth hormone levels. This compound is valuable for research applications related to diabetes and metabolic disorders. -
Somatostatin Neuropeptide
Cortistatin-29 (human) is a somatostatin neuropeptide that modulates a variety of biological functions by interacting with somatostatin receptors. This compound exhibits key biological activities, including anti-inflammatory effects and regulation of pain pathways, making it relevant for research applications in cancer, inflammation, autoimmunity, fibrosis, and pain management. Its unique biological profile allows for exploration of potential therapeutic strategies targeting these conditions. -
sst4 Agonist
NNC 26-9100 is a selective full agonist of the somatostatin sst4 receptor, exhibiting a Ki of 6 nM and an EC50 of 2 nM. This compound has been demonstrated to reduce total soluble Aβ42 levels while increasing neprilysin activity in the brain, suggesting a potential role in neuroprotection. NNC 26-9100 may be valuable for research applications focused on neurodegenerative disorders and cognitive enhancement. -
SSTR4 Agonist
SSTR4 Agonist 2 is a selective agonist of the somatostatin receptor subtype 4 (SSTR4), which plays a critical role in modulating nociceptive and inflammatory pathways. This compound exhibits significant biological activity by engaging the SSTR4 pathway, making it a valuable tool for investigating medical disorders associated with SSTR4 dysfunction. Its potential research applications include studying pain mechanisms and inflammation regulation. -
Somatostatin Receptors Activator
Veldoreotide is a somatostatin receptor activator that selectively binds to and activates somatostatin receptors 2, 4, and 5. This compound effectively inhibits growth hormone secretion in adenomas, presenting a potential advantage over other somatostatin analogues. Additionally, Veldoreotide may serve as a pain modulating agent, making it relevant for research in endocrine disorders and pain management strategies. -
Neuroavtive Peptide
[Tyr11]-Somatostatin is a neuroactive peptide that modulates various physiological processes by targeting somatostatin receptors. This compound is essential for studying the role of neuroactive substances in retinal physiology and their implications in various neurobiological research applications. Its use in proteomics research contributes to a deeper understanding of neuronal signaling pathways and potential therapeutic targets. -
SSTR2 Agonist
Seglitide, a potent agonist of the somatostatin receptor 2 (SSTR2), exhibits important biological activities including antihypertensive effects and the inhibition of plasma glucagon and growth hormone. This compound also acts as a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide is valuable for research focusing on diabetes and related metabolic disorders, providing insights into somatostatin signaling pathways and their therapeutic potential. -
Somatostatin Agonist
Pasireotide pamoate is a long-acting somatostatin analogue that primarily targets somatostatin receptors (sst1/2/3/4/5) with notable binding affinity (pKi=8.2/9.0/9.1/<7.0/9.9). This compound demonstrates significant antisecretory, antiproliferative, and proapoptotic properties, making it valuable for research on neuroendocrine tumors and disorders related to dysregulated hormone secretion. Its diverse biological activities support investigations into therapeutic approaches for various endocrine-related pathologies. -
Somatostatin (1-28) Derivative
[Nle8] Somatostatin (1-28) is a derivative of somatostatin (1-28) in which norleucine substitutes for methionine at position 8. This compound enhances amylase release and elevates cyclic AMP levels in pancreatic acini. It is utilized in research to study pancreatic function and the regulatory mechanisms of peptide hormones in metabolic processes. -
Somatostatin Enhancer
FK962 is a somatostatin enhancer that stimulates the release of this neuropeptide, leading to cognitive-enhancing effects. Its potential anti-dementia properties make it a valuable compound for research focused on neurological diseases and cognitive disorders. Studies exploring FK962 may contribute to a better understanding of somatostatin's role in neuroprotection and cognitive function. -
MMP Inhibitor
Sucrose octasulfate sodium is a potent matrix metalloproteinase (MMP) inhibitor that enhances the release of somatostatin-like immunoreactivity (SLI) from gastric D cells. This compound promotes ulcer healing by increasing endogenous gastric somatostatin levels. Sucrose octasulfate sodium is utilized in research related to chronic wound healing and has shown significant efficacy in improving wound closure in diabetic foot ulcers and venous leg ulcers. Additionally, it serves as a useful pharmaceutical excipient in various applications. -
Somatostatin Receptor Antagonist
PRL 3195 is a somatostatin receptor antagonist that exhibits inhibition constants (Kis) of 6, 17, 66, 1000, and 1000 nM for human somatostatin receptors sst5, sst2, sst3, sst1, and sst4, respectively. This compound is utilized in research to investigate the role of somatostatin signaling in various physiological and pathological processes. Its selective blockade of somatostatin receptors makes it a valuable tool for studying neuroendocrine regulation and potential therapeutic applications in disorders involving somatostatin dysregulation. -
SSTR3 Agonist
SSTR3 Agonist-1 is a selective agonist for the somatostatin receptor subtype 3 (SSTR3), exhibiting an EC50 value of 0.14 nM. This compound has demonstrated efficacy in reducing kidney cystic index, making it a valuable tool in studying autosomal dominant polycystic kidney disease. SSTR3 Agonist-1 facilitates research into therapeutic strategies targeting SSTR3 and its role in renal pathophysiology. -
Somatostatin Receptor 5 Agonist
BIM 23052 is a selective agonist for the somatostatin receptor 5 (SSTR5). It has been shown to enhance gastric emptying, making it a valuable tool for research in gastrointestinal function and disorders. This compound is of particular interest in studies investigating the regulatory mechanisms of hormone action and potential therapeutic applications in gastric motility disorders. -
Antineoplastic Agent
Lanreotide diTFA is a somatostatin analogue that exhibits antineoplastic activity by inhibiting the secretion of growth hormone and other hormones in neuroendocrine tumors. This compound is primarily utilized in research related to carcinoid syndrome and other neuroendocrine disorders. Its mechanism of action involves receptor binding that modulates neuroendocrine function, making it a valuable tool in oncology research. -
Somatostatin Receptor
[Tyr1]-Somatostatin-14 is a bioactive peptide that specifically targets the somatostatin receptor subtype 2 (SSTR2). This compound exhibits high binding affinity, making it a crucial tool for studying receptor signaling pathways and somatostatin-mediated biological processes. Its applications extend to cancer research, neurobiology, and endocrine function studies, allowing researchers to explore therapeutic interventions and physiological mechanisms involving somatostatin receptors. -
Somatostatin Analog
(D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide is a somatostatin analog that demonstrates selective binding affinity with Kd values of 0.61 nM for SSTR5, 11.05 nM for SSTR3, 23.5 nM for SSTR2, 1200 nM for SSTR1, and >1000 nM for SSTR4. This compound exhibits significant biological activity relevant to the regulation of hormonal secretion and inhibition of tumor growth. It is suitable for research applications investigating the role of somatostatin receptors in various physiological and pathological processes. -
Human Somatostatin Receptor Antagonist
BN-81674 is a selective antagonist targeting the human somatostatin sst3 receptor, exhibiting a Ki of 0.92 nM. This compound effectively reverses the inhibition of cyclic AMP accumulation caused by somatostatin at nanomolar concentrations, with an IC50 value of 0.84 nM. BN-81674 is suitable for applications in cancer research, particularly in studies assessing somatostatin signaling pathways and their implications in tumor biology. -
Somatostatin-28 Analog
[Leu8,D-Trp22,Tyr25] Somatostatin-28 is an analog of somatostatin-28, a peptide that plays a critical role in inhibiting hormone secretion and regulating various physiological functions. This modified form enhances the stability and potency of its biological activity, making it useful in research related to neuroendocrine signaling and metabolic regulation. Applications include studying cell signaling pathways, hormonal regulation, and potential therapeutic effects on neuroendocrine tumors. -
SSTR5 Antagonist
SSTR5 antagonist 4 is a highly potent and selective antagonist of the somatostatin subtype 5 receptor (SSTR5), exhibiting IC50 values of 1.3 nM for human SSTR5 and 1.0 nM for mouse SSTR5. This compound demonstrates significant efficacy in the mouse oral glucose tolerance test (OGTT) in high fat diet-induced mice. SSTR5 antagonist 4 is a valuable tool for research into type 2 diabetes and related metabolic disorders. -
SSTR4 Agonist
SSTR4 Agonist 4 is a potent agonist of the somatostatin receptor 4 (SSTR4), which is predominantly expressed in the hippocampus and neocortex, areas crucial for memory and learning. This compound demonstrates significant anti-nociceptive and anti-inflammatory activity in rodent models of both acute and chronic pain. SSTR4 Agonist 4 holds potential for advancing research into pain mechanisms and therapeutic interventions for conditions such as Alzheimer's disease. -
SSTR1 Agonist
L-797591 is a selective agonist of the somatostatin receptor subtype 1 (SSTR1). This compound has demonstrated significant biological activity in modulating neuroendocrine signaling pathways and can be utilized in research focused on neurobiology, cancer biology, and metabolic disorders. Its ability to selectively activate SSTR1 makes it a valuable tool for investigating the physiological and therapeutic roles of somatostatin receptors in various biological systems. -
SRIF Antagonist
AC-178335 is a selective antagonist of somatostatin receptor type 2 (SRIF), exhibiting a Ki value of 172 nM. It effectively inhibits the SRIF-mediated suppression of adenylate cyclase with an IC50 of 5.1 μM in vitro. This compound has demonstrated the capability to induce growth hormone release in anesthetized rat models, making it a valuable tool for investigating the physiological role of somatostatin signaling in endocrine regulation. -
Somatostatin Analog
RC-160 [Lys(Boc)] is an 8-amino acid peptide analog of somatostatin, which primarily acts on somatostatin receptors. It exhibits significant activity in inhibiting hormone secretion and has potential applications in research focused on neuroendocrine regulation and tumor biology. This compound serves as a valuable tool for studying the physiological effects of somatostatin and its analogs in various biological systems. -
Somatostatin Receptor Antagonist
BIM-23056 TFA is a linear octapeptide that serves as a potent antagonist of the somatostatin receptors sst3 and sst5, exhibiting Ki values of 10.8 nM and 5.7 nM, respectively. It effectively inhibits somatostatin-mediated signaling, making it a valuable tool for studying the physiological roles of somatostatin receptors in various biological processes. This compound is suitable for research applications involving endocrine function and neuroendocrine tumor studies. -
Somatostatin Agonist
Tyr-(D-Dab4,Arg5,D-Trp8)-cyclo-Somatostatin-14 (4-11) is a potent somatostatin agonist that selectively activates somatostatin receptors. It demonstrates significant biological activity in modulating hormone secretion and inhibiting cellular proliferation. This compound is primarily utilized in cancer research, particularly in studies focused on tumor growth regulation and neuroendocrine function. -
SSTR Agonist
BIM-23190 is a somatostatin analog that selectively targets somatostatin receptor subtype 2 (SSTR2) and subtype 5 (SSTR5), exhibiting Ki values of 0.34 nM and 11.1 nM, respectively. This compound acts as an agonist, demonstrating significant biological activity in modulating neuroendocrine functions. BIM-23190 is applicable in research areas related to cancer and acromegaly, making it a valuable tool for studying somatostatin signaling pathways and therapeutic interventions. -
SSTR2 Binder
NOTA-TATE is a selective somatostatin receptor 2 (SSTR2) binder. It specifically targets SSTR2-positive tumor cells, facilitating their visualization through PET imaging. This compound is particularly valuable in the research of neuroendocrine tumors, advancing both diagnostic and therapeutic applications in oncology. -
sst2 Receptor Agonist
Sst2 Receptor Agonist-1 is a highly potent agonist for the somatostatin receptor subtype 2 (sst2), exhibiting a Ki value of 0.025 nM and a cAMP IC50 of 4.8 nM. It effectively inhibits growth hormone (GH) secretion in rats and demonstrates anti-angiogenic properties by preventing ocular neovascular lesion formation. This compound is valuable for research in endocrine regulation and angiogenesis. -
Somatostatin Analogue
Axareotide is a synthetic analogue of somatostatin that acts primarily on somatostatin receptors. It is known for its inhibitory effects on hormone secretion, particularly growth hormone and insulin. Axareotide is utilized in research focused on neuroendocrine tumors, acromegaly, and other conditions associated with abnormal hormone levels, providing valuable insights into somatostatin signaling pathways. -
Somatostatin Analogue
Wy 41747 is a long-acting somatostatin analogue that primarily targets somatostatin receptors. This compound exhibits significant biological activity in modulating hormone secretion and is primarily utilized in research focused on diabetes mellitus and related endocrine disorders. Its prolonged action enables detailed studies of the physiological effects and therapeutic potential of somatostatin analogues in metabolic diseases. -
SST4 Agonist
L803 is a selective agonist of the Somatostatin Receptor Subtype 4 (SST4). It has been shown to inhibit L-type calcium channel currents (ICa). This compound is particularly relevant for research involving retinal ganglion cell (RGC) degenerative diseases, such as glaucoma, facilitating the investigation of therapeutic targets for neuroprotection and preservation of RGC function. -
Somatostatin Receptor Agonist
L-779976 is a somatostatin receptor agonist that exhibits notable anxiolytic effects. When administered into the amygdala and septum of rat brains, it has been shown to modulate anxiety-related behaviors through its complex interactions with somatostatin receptors. This compound is instrumental in research applications focusing on anxiety disorders and neuropharmacology, enabling the investigation of somatostatin's role in stress responses and emotional regulation. -
Somatostatin Receptor Inhibitor
SRA880 free base is a somatostatin receptor inhibitor, specifically targeting the somatostatin-1 autoreceptor. This compound exhibits antidepressant-modulating effects and has been shown to enhance the efficacy of imipramine, resulting in antidepressant-like outcomes. Additionally, SRA880 influences brain-derived neurotrophic factor (BDNF) mRNA expression and modulates the phosphorylation of associated proteins, making it a valuable tool in neurobiological research focusing on mood disorders and related pathways. -
Somatostatin Analog
Ilatreotide is a potent somatostatin analog known for its improved oral bioactivity. It effectively suppresses both fasting and postprandial secretion of various gastrointestinal and pancreatic hormones. This compound is valuable for research into gastroenteropancreatic tumors and offers insights into hormonal regulation in related pathologies. -
Somatostatin Receptor Agonist
SSTR4 Agonist 5 is a potent, orally active agonist of the somatostatin receptor 4 (SSTR4) with an EC50 value of 0.228 nM. Demonstrating considerable stability in human and rat liver microsomes, this compound has shown effectiveness in inhibiting mechanical hyperalgesia in rat models. It is a valuable tool for research applications involving pain mechanisms and SSTR4-related pathways. -
Somatostatin Receptor Agonist
L-054522 is an agonist for somatostatin receptor subtype 2, featuring a Kd of 0.01 nM. This compound effectively inhibits growth hormone secretion from rat primary pituitary cells with an IC50 of 0.05 nM, as well as glucagon and insulin release from isolated mouse pancreatic islet cells, exhibiting IC50 values of 0.05 nM and 12 nM, respectively. L-054522 serves as a valuable tool for exploring somatostatin signaling and its impact on endocrine functions in research applications. -
Somatostatin Analogue
(D-Trp8,D-Cys14)-Somatostatin-14 is a synthetic analogue of somatostatin, targeting somatostatin receptors. This peptide exhibits significant biological activity in modulating hormonal secretion and inhibiting cell proliferation, making it valuable in research related to metabolic disorders and neuroendocrine tumors. Its unique structure allows for enhanced stability and potency in various biological assays. -
Somatostatin Receptor Inhibitor
Des-threoninol-octreotide is a potent somatostatin receptor inhibitor, primarily targeting the mSSTR2b, rSSTR5, and hSSTR5 receptor subtypes. This compound demonstrates high inhibitory activity with IC50 values of 13.62 nM, 10.63 nM, and 10.95 nM, respectively. It is valuable for research applications exploring neuroendocrine regulation, peptide hormone signaling, and potential therapeutic interventions involving somatostatin pathways. -
Somatostatin Agonist
Pasireotide (diaspartate) is a long-acting somatostatin agonist targeting somatostatin receptors sst1, sst2, sst3, sst4, and sst5, with pKi values of 8.2, 9.0, 9.1, <7.0, and 9.9, respectively. This cyclohexapeptide compound demonstrates significant antisecretory, antiproliferative, and proapoptotic activities. Its diverse biological effects make it a valuable tool for research applications in endocrinology and oncology, particularly in the study of neuroendocrine tumors and hormonal regulation. -
Somatostatin Analogue
Nendratareotide is a somatostatin analogue that primarily targets somatostatin receptors. It exhibits inhibitory effects on hormone secretion, making it valuable in the treatment of neuroendocrine tumors and acromegaly. This compound is also utilized in research focused on understanding the physiological roles of somatostatin and its impact on glucose metabolism and cell proliferation. -
Neuropeptide
Cortistatin-29 is a rat neuropeptide that targets somatostatin receptors (SSTRs) with high affinity, exhibiting IC50 values of 2.8 nM for SSTR1, 7.1 nM for SSTR2, 0.2 nM for SSTR3, 3.0 nM for SSTR4, and 13.7 nM for SSTR5. This compound is known to alleviate neuropathic pain and demonstrates anti-fibrotic properties. Its diverse biological activities make it a valuable tool for research in neurobiology and fibrosis-related studies. -
SSTR5 Antagonist
SSTR5 antagonist 6 is a selective antagonist for somatostatin receptor subtype 5 (SSTR5), exhibiting an IC50 of 24 nM. This compound plays a significant role in modulating signaling pathways associated with glucose homeostasis and insulin regulation, making it valuable for research related to type 2 diabetes. Its oral bioactivity enhances its potential for in vivo studies, facilitating exploration of SSTR5's impact on metabolic disorders. -
SST1 Antagonist
SST1 receptor antagonist-1 is a selective antagonist of the Somatostatin receptor 1 (SST1), exhibiting pKds of 9.11 and 8.79 for rat and human SST1, respectively. This compound is utilized in research focused on retinal and endocrine dysfunctions, as well as cancer and neuropsychiatric disorders, making it a valuable tool for investigating the role of SST1 in various biological systems.
